


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula (I):



wherein:

X is O;

Y is a bond[~~[,] or~~] or C₁₋₆ alkylene optionally substituted by C₁₋₄ alkyl or phenyl, ~~phenylene optionally substituted by halogen, hydroxy, C₁₋₄ alkyl or C₁₋₄ alkoxy, or heterocyclene optionally substituted by halogen, hydroxy, C₁₋₄ alkyl or C₁₋₄ alkoxy;~~

Z is CO₂R^b, NHS(O)₂CF₃, S(O)₂OH, OCH₂CO₂R^b or tetrazolyl;

R¹ is aryl;

R² is hydrogen, C₁₋₆ alkyl, aryl or heterocyclyl;

R^a and R^b are, independently, hydrogen or C₁₋₄ alkyl; or when R² is aryl or heterocyclyl

R^a optionally is C₂₋₃ alkylene forming a ring with an ortho position on R²;

R^c is hydrogen or hydroxy;

wherein, unless stated otherwise, the foregoing aryl and heterocyclyl moieties are optionally substituted by: halogen, cyano, nitro, hydroxy, oxo, S(O)_pR⁴, OC(O)NR⁵R⁶, NR⁷R⁸, NR⁹C(O)R¹⁰, NR¹¹C(O)NR¹²R¹³, S(O)₂NR¹⁴R¹⁵, NR¹⁶S(O)₂R¹⁷, C(O)NR¹⁸R¹⁹, C(O)R²⁰, CO₂R²¹, NR²²CO₂R²³, C₁₋₆ alkyl, CF₃, C₁₋₆ alkoxy(C₁₋₆)alkyl, C₁₋₆ alkoxy, OCF₃, C₁₋₆ alkoxy(C₁₋₆)alkoxy, C₁₋₆ alkylthio, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl optionally substituted by C₁₋₄ alkyl or oxo, methylenedioxy, difluoromethylenedioxy, phenyl, phenyl(C₁₋₄)alkyl, phenoxy, phenylthio, phenyl(C₁₋₄)alkoxy, heterocyclyl, heterocyclyl(C₁₋₄)alkyl, heterocycloxy or

heterocyclyl(C₁₋₄)alkoxy; wherein any of the immediately foregoing phenyl and heterocyclyl moieties are optionally substituted with halogen, hydroxy, nitro, S(O)_q(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl), S(O)₂N(C₁₋₄ alkyl)₂ and these alkyl groups optionally join to form a ring as described for R⁵ and R⁶ below, cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂ and these alkyl groups optionally join to form a ring as described for R⁵ and R⁶ below, CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃;

p and q are, independently, 0, 1 or 2;

R³, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁸, R¹⁹, R²⁰, R²¹ and R²² are, independently, hydrogen, C₁₋₆ alkyl optionally substituted by halogen, hydroxy or C₃₋₁₀ cycloalkyl, CH₂(C₂₋₆ alkenyl), phenyl optionally substituted by halogen, hydroxy, nitro, NH₂, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂ and these alkyl groups optionally join to form a ring as described for R⁵ and R⁶ below, S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl), S(O)₂N(C₁₋₄ alkyl)₂ and these alkyl groups optionally join to form a ring as described for R⁵ and R⁶ below, cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂ and these alkyl groups optionally join to form a ring as described for R⁵ and R⁶ below, CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃) or heterocyclyl optionally substituted by halogen, hydroxy, nitro, NH₂, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂ and these alkyl groups optionally join to form a ring as described for R⁵ and R⁶ below, S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl), S(O)₂N(C₁₋₄ alkyl)₂ and these alkyl groups optionally join to form a ring as described for R⁵ and R⁶ below, cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂ and these alkyl groups optionally join to form a ring as described for R⁵ and R⁶ below, CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃;

alternatively NR⁵R⁶, NR⁷R⁸, NR¹²R¹³, NR¹⁴R¹⁵, NR¹⁸R¹⁹, independently, form a 4-7 membered heterocyclic ring, azetidine, pyrrolidine, piperidine, azepine, morpholine or piperazine, the latter optionally substituted by C₁₋₄ alkyl on the distal nitrogen;

R⁴, R¹⁷ and R²³ are, independently, C₁₋₆ alkyl optionally substituted by halogen, hydroxy or C₃₋₁₀ cycloalkyl, CH₂(C₂₋₆ alkenyl), phenyl itself optionally substituted by halogen, hydroxy, nitro, NH₂, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂ and these alkyl groups optionally join to form a ring as

described for R^5 and R^6 above, $S(O)_2(C_{1-4} \text{ alkyl})$, $S(O)_2NH_2$, $S(O)_2NH(C_{1-4} \text{ alkyl})$, $S(O)_2N(C_{1-4} \text{ alkyl})_2$ and these alkyl groups optionally join to form a ring as described for R^5 and R^6 above, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, $C(O)NH_2$, $C(O)NH(C_{1-4} \text{ alkyl})$, $C(O)N(C_{1-4} \text{ alkyl})_2$ and these alkyl groups optionally join to form a ring as described for R^5 and R^6 above, CO_2H , $CO_2(C_{1-4} \text{ alkyl})$, $NHC(O)(C_{1-4} \text{ alkyl})$, $NHS(O)_2(C_{1-4} \text{ alkyl})$, $C(O)(C_{1-4} \text{ alkyl})$, CF_3 or OCF_3) or heterocyclyl optionally substituted by halogen, hydroxy, nitro, NH_2 , $NH(C_{1-4} \text{ alkyl})$, $N(C_{1-4} \text{ alkyl})_2$ and these alkyl groups optionally join to form a ring as described for R^5 and R^6 above, $S(O)_2(C_{1-4} \text{ alkyl})$, $S(O)_2NH_2$, $S(O)_2NH(C_{1-4} \text{ alkyl})$, $S(O)_2N(C_{1-4} \text{ alkyl})_2$ and these alkyl groups optionally join to form a ring as described for R^5 and R^6 above, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, $C(O)NH_2$, $C(O)NH(C_{1-4} \text{ alkyl})$, $C(O)N(C_{1-4} \text{ alkyl})_2$ and these alkyl groups optionally join to form a ring as described for R^5 and R^6 above, CO_2H , $CO_2(C_{1-4} \text{ alkyl})$, $NHC(O)(C_{1-4} \text{ alkyl})$, $NHS(O)_2(C_{1-4} \text{ alkyl})$, $C(O)(C_{1-4} \text{ alkyl})$, CF_3 or OCF_3 ;

or an N-oxide thereof; or a pharmaceutically acceptable salt thereof; or a solvate thereof.

2. (Original) A compound as claimed in claim 1 wherein R^1 is phenyl optionally substituted with halogen, C_{1-4} alkyl or C_{1-4} alkoxy.

3. (Cancelled)

4. (Previously Presented) A compound as claimed in claim 1 wherein R^a and R^c are both hydrogen.


5. (Previously Presented) A compound as claimed in claim 1 wherein Z is CO_2R^b .

6. (Previously Presented) A compound as claimed in claim 1 wherein Y is a bond or alkylene optionally substituted by C_{1-4} alkyl; R^a is hydrogen; and, R^2 is hydrogen, C_{1-6} alkyl, phenyl optionally substituted by halogen, C_{1-4} alkyl, C_{1-4} alkoxy or $NHC(O)(C_{1-4} \text{ alkyl})$ or heterocyclyl optionally substituted by halogen, C_{1-4} alkyl or C_{1-4} alkoxy.


7. (Cancelled)

8. (Previously Presented) A process for preparing a compound of formula (I) as claimed in claim 1, the process comprising:

a) coupling a compound of formula (II):




with a compound of formula (III):




wherein L is a suitable leaving group;

b) when Rᵃ is hydrogen and Z is CO₂Rᵇ, reductive amination of a compound (II) with a compound of formula (IV):




wherein Rᵇ is C₁-₄ alkyl, in the presence of NaBH(OAc)₃ and acetic acid, or NaBH₃CN in a suitable solvent, optionally followed by hydrolysis of the ester group;

c) when Y is a bond, R¹ and Rᵇ are both hydrogen and Z is CO₂H, a three component coupling of a compound of formula (II) with compounds of formula (V) and (VI):




in a suitable solvent at a suitable elevated temperature;

d) when Y is a bond and Z is CO₂H, performing a nitrile hydrolysis on a compound of formula (XI):



e) when Z is tetrazol-5-yl, reacting a compound of formula (XI) with $(\text{CH}_3)_3\text{SiN}_3$ and $(\text{Bu}_3\text{Sn})_2\text{O}$ at an elevated temperature;

f) when Z is $\text{NHS}(\text{O})_2\text{CF}_3$, reacting a compound of formula (XII):



with triflic anhydride at a reduced temperature.

9. (Original) A pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof as claimed in claim 1, and a pharmaceutically acceptable adjuvant, diluent or carrier.

10-11. (Cancelled)

12. (Withdrawn) A method of treating a chemokine mediated disease state in a mammal suffering from, or at risk of, said disease, which comprises administering a compound of formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof as claimed in claim 1.

13-14. (Cancelled)